This is the authors' abstract. We don't add key points for this paper.
RyR1, an enormous, approximately 2.2 MDa, tetrameric calcium-release channel in the sarcoplasmic reticulum (SR) of skeletal muscle, is essential for excitation-contraction coupling. Pathogenic mutations in RyR1 cause RyR1-related myopathies. ARM210 (S48168), a Rycal-class drug, has shown promise in treating RyR1-related myopathies in a recently concluded phase 1b clinical trial. Structural studies revealed that ARM210 binds to the peripheral RY1&2 domain of RyR1, stabilizing it in a closed state to prevent aberrant SR Ca 2+ leak. Here, we investigate ARM210’s mechanism of action at the atomistic level using extensive all-atom (~2.5 million atoms) explicit-solvent molecular dynamics simulations totaling 36.6 μs. Simulations revealed a long-range allosteric pathway in the wild-type RyR1 that propagates over 200 Å, linking the RY1&2 domain to the pore-forming S6 helices of adjacent protomers and enabling pore opening. Subsequently, we demonstrated that ARM210 binding stabilizes the RY1&2 domain in a closed conformation, rigidifying the cytosolic shell and activation core and disrupting the allosteric network necessary for pore dilation. These findings describe a plausible mode of action for how ARM210 stabilizes RyR1 in a closed state by modulating long-range allostery. Furthermore, we show that this allosteric regulatory network is perturbed by the oxidative stress-mimicking C3892D mutation near the Ca 2+ activator site, identified via mass spectrometry, live-cell fluorescence microscopy, and electrophysiology.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sanbonmatsu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: